Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with child-pugh B cirrhosis

Oncology (Switzerland)

Volumn 84, Issue 1, 2012, Pages 32-38

  Dhooge, Marion ^a   Coriat, Romain ^a,b   Mir, Olivier ^a,b   Perkins, Géraldine ^a,b   Brezault, Catherine ^a   Boudou Rouquette, Pascaline ^a,b   Goldwasser, François ^a,b   Chaussade, Stanislas ^a,b  

^a Institut Cochin   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Chemotherapy; Child Pugh; Cirrhotic patients; Gemcitabine; Hepatocellular carcinoma; Oxaliplatin

Indexed keywords

GEMCITABINE; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; BODY COMPOSITION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; ESOPHAGUS VARICES BLEEDING; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MUSCLE ATROPHY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCORING SYSTEM; THROMBOCYTOPENIA; TREATMENT RESPONSE; VEIN LIGATION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, HEPATOCELLULAR; DEOXYCYTIDINE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84867484763     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342763     Document Type: Article

References (27)

1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma N Engl J Med 2008; 359: 378-390
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D, Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34
3. Hollebecque A, Cattan S, Romano O, Sergent G, Mourad A, Louvet A, Dharancy S, Boleslawski E, Truant S, Pruvot FR, Hebbar M, Ernst O, Mathurin P: Safety and efficacy of sorafenib in hepatocellular carcinoma: The impact of the Child-Pugh score. Aliment Pharmacol Ther 2012; 34: 1193-1201
4. Ozenne V, Paradis V, Pernot S, Castelnau C, Vullierme MP, Bouattour M, Valla D, Farges O, Degos F: Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib. Eur J Gastroenterol Hepatol 2010; 22: 1106-1110
5. Alexandre J, Tigaud JM, Gross-Goupil M, Gornet JM, Romain D, Azoulay D, Misset JL, Goldwasser F: Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 2002; 25: 198-203 (Pubitemid 34293079)
6. Coriat R, Mir O, Cessot A, Brezault C, Ropert S, Durand JP, Cacheux W, Chaussade S, Goldwasser F: Feasibility of oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX-4) in cirrhotic or liver transplant patients: Experience in a cohort of advanced hepatocellular carcinoma patients. Invest New Drugs 2012; 30: 376-381
7. Louafi S, Boige V, Ducreux M, Bonyhay L, Mansourbakht T, de Baere T, Asnacios A, Hannoun L, Poynard T, Taieb J: Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC): Results of a phase II study. Cancer 2007; 109: 1384-1390 (Pubitemid 46466566)
8. Taieb J, Bonyhay L, Golli L, Ducreux M, Boleslawski E, Tigaud JM, de Baere T, Mansourbakht T, Delgado MA, Hannoun L, Poynard T, Boige V: Gemcitabine plus oxaliplatin for patients with advanced hepatocellular carcinoma using two different schedules Cancer 2003; 98: 2664-2670 (Pubitemid 37509531)
9. Faivre S, Le Chevalier T, Monnerat C, Lokiec F, Novello S, Taieb J, Pautier P, Lhomme C, Ruffie P, Kayitalire L, Armand JP, Raymond E: Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma. Ann Oncol 2002; 13: 1479-1489
10. Faivre S, Raymond E, Woynarowski JM, Cvitkovic E: Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother Pharmacol 1999; 44: 117-123 (Pubitemid 29297057)
11. Mir O, Alexandre J, Ropert S, Amsellem- Ouazana D, Flam T, Beuzeboc P, Zerbib M, Debre B, Guillevin L, Goldwasser F: Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs 2005; 16: 1017-1021 (Pubitemid 41416093)
12. Mir O, Coriat R, Boudou-Rouquette P, Ropert S, Durand JP, Cessot A, Mallet V, Sogni P, Chaussade S, Pol S, Goldwasser F: Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol 2012, E-pub ahead of print
13. Taieb J, Barbare JC, Rougier P: Medical treatments for hepatocellular carcinoma (HCC): What's next? Ann Oncol 2006; 17(suppl 10):x308-x314 (Pubitemid 44542028)
14. Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, Baracos VE: Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: A population-based study. Lancet Oncol 2008; 9: 629-635
15. Boige V, Barbare JC, Rosmorduc O: Use of sorafenib (Nexavar) in the treatment of hepatocellular carcinoma: PRODIGE AFEF recommendations. Gastroenterol Clin Biol 2008; 32: 3-7 (Pubitemid 351625521)
16. Caussanel JP, Levi F, Brienza S, Misset JL, Itzhaki M, Adam R, Milano G, Hecquet B, Mathe G: Phase I trial of 5-day continuous venous infusion of oxaliplatin at circadian rhythm-modulated rate compared with constant rate. J Natl Cancer Inst 1990; 82: 1046- 1050 (Pubitemid 20204976)
17. Prado CM, Baracos VE, McCargar LJ, Reiman T, Mourtzakis M, Tonkin K, Mackey JR, Koski S, Pituskin E, Sawyer MB: Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res 2009; 15: 2920- 2926
18. Prado CM, Lima IS, Baracos VE, Bies RR, McCargar LJ, Reiman T, Mackey JR, Kuzma M, Damaraju VL, Sawyer MB: An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother Pharmacol 2010; 67: 93-101
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
20. Chiu J, Tang YF, Yao TJ, Wong A, Wong H, Leung R, Chan P, Cheung TT, Chan AC, Pang R, Fan ST, Poon R, Yau T: The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: A retrospective analysis of efficacy, safety, and survival benefits. Cancer DOI: 10.1002/ cncr.27543
21. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, Dousset B, Morel P, Soubrane O, Chaussade S, Mentha G, Terris B: Severe hepatic sinusoidal obstruction associated with oxaliplatin- based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004; 15: 460-466 (Pubitemid 38444550)
22. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi SS, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M, Taieb J: Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: Results of a multicenter phase 2 study. Cancer 2008; 112: 2733-2739 (Pubitemid 351969218)
23. Sanoff HK, Goldberg RM, Pignone MP: Assessing the quality of initial consultations regarding adjuvant colon cancer therapy. Clin Colorectal Cancer 2010; 9: 113-118
24. Sun W, Sohal D, Haller DG, Mykulowycz K, Rosen M, Soulen MC, Caparro M, Teitelbaum UR, Giantonio B, O'Dwyer PJ, Shaked A, Reddy R, Olthoff K: Phase 2 trial of bevacizumab, capecitabine, and oxaliplatin in treatment of advanced hepatocellular carcinoma Cancer 2011; 117: 3187-3192
25. Meza-Junco J, Montano-Loza A, Prado CMM, Lieffers JR, Baracos VE, Bain V, Spratlin JL, Sawyer MB: Sarcopenia in patients (pts) with hepatocelluar carcinoma (HCC). J Clin Oncol 2011; 29:e14570
26. Yau T, Yao TJ, Chan P, Wong H, Pang R, Fan ST, Poon RT: The significance of early alphafetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib. Oncologist 2011; 16: 1270-1279
27. Mir O, Coriat R, Blanchet B, Durand JP, Boudou- Rouquette P, Michels J, Ropert S, Vidal M, Pol S, Chaussade S, Goldwasser F: Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 2012; 7:e37563